141 related articles for article (PubMed ID: 37556505)
1. Allosteric Regulation of Switch-II Domain Controls KRAS Oncogenicity.
Yang MH; Tran TH; Hunt B; Agnor R; Johnson CW; Shui B; Waybright TJ; Nowak JA; Stephen AG; Simanshu DK; Haigis KM
Cancer Res; 2023 Oct; 83(19):3176-3183. PubMed ID: 37556505
[TBL] [Abstract][Full Text] [Related]
2. A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation.
Yin G; Kistler S; George SD; Kuhlmann N; Garvey L; Huynh M; Bagni RK; Lammers M; Der CJ; Campbell SL
J Biol Chem; 2017 Mar; 292(11):4446-4456. PubMed ID: 28154176
[TBL] [Abstract][Full Text] [Related]
3. Insights into K-Ras 4B regulation by post-translational lysine acetylation.
Knyphausen P; Lang F; Baldus L; Extra A; Lammers M
Biol Chem; 2016 Oct; 397(10):1071-85. PubMed ID: 27176741
[TBL] [Abstract][Full Text] [Related]
4. KRAS K104 modification affects the KRAS
Chen CC; Hsu CY; Lin HY; Zeng HQ; Cheng KH; Wu CW; Tsai EM; Hsieh TH
Sci Rep; 2020 Oct; 10(1):17447. PubMed ID: 33060649
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of the atypical activation mechanism of KRAS
Bera AK; Lu J; Wales TE; Gondi S; Gurbani D; Nelson A; Engen JR; Westover KD
J Biol Chem; 2019 Sep; 294(38):13964-13972. PubMed ID: 31341022
[TBL] [Abstract][Full Text] [Related]
6. Regulation of RAS oncogenicity by acetylation.
Yang MH; Nickerson S; Kim ET; Liot C; Laurent G; Spang R; Philips MR; Shan Y; Shaw DE; Bar-Sagi D; Haigis MC; Haigis KM
Proc Natl Acad Sci U S A; 2012 Jul; 109(27):10843-8. PubMed ID: 22711838
[TBL] [Abstract][Full Text] [Related]
7. Conformational resolution of nucleotide cycling and effector interactions for multiple small GTPases determined in parallel.
Killoran RC; Smith MJ
J Biol Chem; 2019 Jun; 294(25):9937-9948. PubMed ID: 31088913
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
[TBL] [Abstract][Full Text] [Related]
9. The molecular basis for immune dysregulation by the hyperactivated E62K mutant of the GTPase RAC2.
Arrington ME; Temple B; Schaefer A; Campbell SL
J Biol Chem; 2020 Aug; 295(34):12130-12142. PubMed ID: 32636302
[TBL] [Abstract][Full Text] [Related]
10. Synergy and anti-cooperativity in allostery: Molecular dynamics study of WT and oncogenic KRAS-RGL1.
Hacisuleyman A; Erman B
Proteins; 2024 May; 92(5):665-678. PubMed ID: 38153169
[TBL] [Abstract][Full Text] [Related]
11. Biophysical Characterization of RAS-SOS Complexes by Native Mass Spectrometry.
Yun S; Scott E; Laganowsky A
Methods Mol Biol; 2024; 2797():177-193. PubMed ID: 38570460
[TBL] [Abstract][Full Text] [Related]
12. A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers.
Cheng R; Li F; Zhang M; Xia X; Wu J; Gao X; Zhou H; Zhang Z; Huang N; Yang X; Zhang Y; Shen S; Kang T; Liu Z; Xiao F; Yao H; Xu J; Yan C; Zhang N
Cell Res; 2023 Jan; 33(1):30-45. PubMed ID: 36241718
[TBL] [Abstract][Full Text] [Related]
13. Distinct subclasses of small GTPases interact with guanine nucleotide exchange factors in a similar manner.
Day GJ; Mosteller RD; Broek D
Mol Cell Biol; 1998 Dec; 18(12):7444-54. PubMed ID: 9819430
[TBL] [Abstract][Full Text] [Related]
14. Tissue-Specific Oncogenic Activity of KRAS
Poulin EJ; Bera AK; Lu J; Lin YJ; Strasser SD; Paulo JA; Huang TQ; Morales C; Yan W; Cook J; Nowak JA; Brubaker DK; Joughin BA; Johnson CW; DeStefanis RA; Ghazi PC; Gondi S; Wales TE; Iacob RE; Bogdanova L; Gierut JJ; Li Y; Engen JR; Perez-Mancera PA; Braun BS; Gygi SP; Lauffenburger DA; Westover KD; Haigis KM
Cancer Discov; 2019 Jun; 9(6):738-755. PubMed ID: 30952657
[No Abstract] [Full Text] [Related]
15. The role of the conserved switch II glutamate in guanine nucleotide exchange factor-mediated nucleotide exchange of GTP-binding proteins.
Gasper R; Thomas C; Ahmadian MR; Wittinghofer A
J Mol Biol; 2008 May; 379(1):51-63. PubMed ID: 18440551
[TBL] [Abstract][Full Text] [Related]
16. Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors.
Akkapeddi P; Hattori T; Khan I; Glasser E; Koide A; Ketavarapu G; Whaby M; Zuberi M; Teng KW; Lefler J; Maso L; Bang I; Ostrowski MC; O'Bryan JP; Koide S
Proc Natl Acad Sci U S A; 2023 Jul; 120(28):e2302485120. PubMed ID: 37399416
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide CRISPR Screen to Identify Genes that Suppress Transformation in the Presence of Endogenous Kras
Huang J; Chen M; Xu ES; Luo L; Ma Y; Huang W; Floyd W; Klann TS; Kim SY; Gersbach CA; Cardona DM; Kirsch DG
Sci Rep; 2019 Nov; 9(1):17220. PubMed ID: 31748650
[TBL] [Abstract][Full Text] [Related]
18. Structures of RGL1 RAS-Association Domain in Complex with KRAS and the Oncogenic G12V Mutant.
Eves BJ; Gebregiworgis T; Gasmi-Seabrook GMC; Kuntz DA; Privé GG; Marshall CB; Ikura M
J Mol Biol; 2022 May; 434(9):167527. PubMed ID: 35257782
[TBL] [Abstract][Full Text] [Related]
19. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
20. Molecular assemblies of the catalytic domain of SOS with KRas and oncogenic mutants.
Moghadamchargari Z; Shirzadeh M; Liu C; Schrecke S; Packianathan C; Russell DH; Zhao M; Laganowsky A
Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33723061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
